Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze For The Treatment Of Acute Lymphoblastic Leukemia And Lymphoblastic Lymphoma
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner Jazz Pharmaceuticals plc (NASDAQ:JAZZ), ("Jazz") has been granted marketing authorization by the European Commission (EC) for Enrylaze®